AstraZeneca PLC - American Depositary Shares (AZN)
84.69
+0.86 (1.03%)
NASDAQ · Last Trade: Oct 18th, 10:41 AM EDT
Detailed Quote
Previous Close
83.83
Open
83.83
Bid
82.36
Ask
85.30
Day's Range
83.65 - 85.06
52 Week Range
61.24 - 86.57
Volume
3,125,962
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
1.030 (1.22%)
1 Month Average Volume
6,065,088
Chart
About AstraZeneca PLC - American Depositary Shares (AZN)
AstraZeneca is a global biopharmaceutical company that focuses on the research, development, and manufacturing of a wide range of prescription medications. The company's primary areas of expertise include oncology, respiratory diseases, cardiovascular systems, and immunology, with a commitment to advancing innovative treatments that improve patient outcomes. AstraZeneca collaborates with healthcare professionals, researchers, and academic institutions to drive scientific advancements and ensure that their therapies reach those in need. Through its extensive portfolio, the company aims to address some of the world’s most pressing health challenges while maintaining a strong emphasis on sustainability and corporate responsibility. Read More
Positive results from the DESTINY-Breast05 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival (IDFS) in patients with a high risk of disease recurrence. The trial compared ENHERTU with trastuzumab emtansine (T-DM1) as a post-neoadjuvant treatment (after surgery) in patients with HER2-positive early breast cancer with residual invasive disease in the breast and/or axillary lymph nodes after neoadjuvant treatment.
Positive results from the DESTINY-Breast11 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab (THP) in the neoadjuvant setting (before surgery) demonstrated a statistically significant and clinically meaningful improvement in the pathologic complete response (pCR) rate. The trial compared ENHERTU followed by THP with dose-dense doxorubicin and cyclophosphamide followed by THP (ddAC-THP) in patients with high-risk, locally advanced HER2-positive early-stage breast cancer. Pathologic complete response is defined as no evidence of invasive cancer cells in the removed breast tissue and lymph nodes following treatment.
AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab -ekko) has been approved in the US for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP), a complex epithelial-driven inflammatory condition. TEZSPIRE is the first and only biologic that targets thymic stromal lymphopoietin (TSLP) to be approved for CRSwNP.
INVO Fertility Inc (NASDAQ:IVF) shares are trading lower on Thursday as investors book profits following White House announcements aimed at making fertility treatments more affordable and accessible.
Positive results from the POTOMAC Phase III trial showed adding one year of treatment with AstraZeneca’s IMFINZI® (durvalumab) to BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC) compared to BCG treatment alone.
Positive results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of overall survival (OS) versus chemotherapy alone. Patients were treated with neoadjuvant IMFINZI in combination with chemotherapy before surgery, followed by adjuvant IMFINZI in combination with chemotherapy, then IMFINZI monotherapy. The trial evaluated this regimen versus perioperative chemotherapy alone for patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers.
Merck's KEYNOTE-B96 trial shows Keytruda with chemotherapy improves survival in platinum-resistant recurrent ovarian cancer with a consistent safety profile.
AstraZeneca today announces the unveiling of its newly-expanded, state-of-the-art manufacturing facility in Coppell, Texas. The expansion project will double the production of Lokelma for the benefit of patients in the United States and around the world.
Discover AstraZeneca, a top-quality stock with strong growth, high ROIC, and robust cash flow. A prime candidate for long-term investors seeking durable competitive advantages.
Absci (NASDAQ: ABSI), a pioneer in AI-driven drug discovery, is making significant strides with its "Integrated Drug Creation™ Platform," promising to revolutionize how new medicines are brought to market. By combining generative artificial intelligence with high-throughput wet lab technologies, Absci aims to drastically cut down the time and cost associated
AstraZeneca advances its ambition to redefine cancer care with new data across its diverse, industry-leading portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress, October 17-21, 2025.
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE:PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of 2025. This latest payout marks a significant milestone: the company's 348th consecutive quarterly dividend. The unwavering consistency of
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE: PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of 2025. This payment marks a significant milestone as the company's 348th consecutive quarterly dividend, a testament to its
AstraZeneca will invest $4.5 billion in a Virginia facility, creating 3,600 jobs and producing advanced cancer and metabolic medicines using AI and automation.
